Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: GOG 9923:A PHASE I STUDY OF CARBOPLATIN/PACLITAXEL/CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865, IND #7921) AND CTEP-SUPPLIED AGENT ABT-888 (NSC #737664 IND# 77840) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE

 


GOG 9923:A PHASE I STUDY OF CARBOPLATIN/PACLITAXEL/CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865, IND #7921) AND CTEP-SUPPLIED AGENT ABT-888 (NSC #737664 IND# 77840) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE


Trial Focus

Female Reproductive Cancer

Objective

         Not available at this time

IRB Protocol #

11-0636

Trial Status

OPEN

Principle Investigator

KIAN BEHBAKHT

Sponsor

GOG

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : Not available at this time // Not available at this timeNot available at this time